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AUCThe delivery of personalized antimicrobial therapy is a critical component in the treatment of patients with inva-
sive infections. Vancomycin, the drug of choice for infections due to methicillin-resistant Staphylococcus aureus,
requires the use of therapeutic drug monitoring (TDM) for delivery of optimal therapy. Current guidance on
vancomycin TDM includes the measurement of a trough concentration as a surrogate for achieving an AUC to
minimum inhibitory concentration (MIC) by broth microdilution (AUC/MICBMD) ratio ≥400. Although trough-
only monitoring has been widely integrated into clinical practice, there is a high degree of inter-individual
variability between a measured trough concentration and the actual AUC value. The therapeutic discordance be-
tween AUC and trough may lead to suboptimal outcomes among patients with infections due to less susceptible
pathogens or unnecessarily increase the probability of acute kidney injury (AKI) in others. Given the potentially
narrow vancomycin AUC range for optimal effect and minimal AKI, clinicians need a “real-time” system to predict
accurately the AUC with limited pharmacokinetic (PK) sampling. This article reviews two innovative approaches
for calculating the vancomycin AUC in clinical practice based on one or two drug concentrations. One such approach
involves the use of Bayesian computer software programs to estimate the “true” vancomycin AUC value with
minimal PK sampling and provide AUC-guided dosing recommendations at the bedside. An alternative involves
use of two concentrations (peak and trough) and simple analytic equations to estimateAUCvalues. Both approaches
provide considerable improvements over the current trough-only concentration monitoring method.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Vancomycin is the cornerstone of therapy for patients with invasive
infections due to methicillin-resistant Staphylococcus aureus (MRSA), the
most prevalent multi-drug resistant pathogen in the world [1]. The risingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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comycin. In the United States alone, over 20 million days of vancomycin
are used annually [2]. Despite its introduction over a half century ago,
the optimal dosing strategy for vancomycin remains undeﬁned. Contem-
porary vancomycin dosing schemes are designed to achieve an area
under the curve (AUC) to minimum inhibitory concentration (MIC)
(AUC/MIC) ratio≥400 for serious infections due toMRSA [3,4]. Although
anAUC/MIC ratio≥400 is the prevailing vancomycin exposure target that
is based on an MIC determined by broth microdilution (AUC/MICBMD),
AUCs are not determined routinely in clinical practice due to the per-
ceived difﬁculty in calculating the AUC [3,4]. Historically, a clinician had
to collect multiple pharmacokinetic (PK) samples and apply the linear-
trapezoidal rule to determine theAUC in a givenpatient [5]. The perceived
difﬁculties associated with determining vancomycin AUC values in “real-
time” have led to the expert guideline committee recommendations to
maintain vancomycin trough concentrations between 15 and 20 mg/L
as a surrogatemarker of an AUC/MICBMD ratio≥400 for serious infections
due toMRSA [3,4]. This recommendation has beenwidely integrated into
clinical practice. However, the clinical beneﬁts ofmaintaining higher van-
comycin trough values have not been well described [6–11]. In addition,
evidence is mounting that the intensive intermittent dosing vancomycin
regimens use to achieve troughs in excess of 15 mg/L may be associated
with increased acute kidney injury (AKI) rates [12].
While trough monitoring is relatively straightforward in most
practice settings, there is a high degree of inter-individual variability be-
tween a measured trough concentration and the actual AUC value [13,
14]. Themathematical discordance between the AUC and trough values
is not surprising and is well-described in the literature [13]. In simple
terms, the AUC is reﬂective of the cumulative exposure for a deﬁned
time period (e.g., 0–24 h). In contrast, the trough is a single point
exposure measurement at the end of the dosing interval. It is unreason-
able to expect a single measurement at the end of the dosing interval to
be representative of the entire concentration-time proﬁle without
incorporating some covariate(s) and parameter assumptions [13,14].
This discrepancy between AUC and trough has clear implications for
clinical practice. Trough values of 15–20mg/L do not guarantee optimal
AUC/MICBMD exposures in patients with infections due to MRSA with
vancomycin MIC values in excess of 1 mg/L. Conversely, a trough of
15–20 mg/L may lead to AUC values that have been associated with an
increased risk of AKI.
The therapeutic discordance between vancomycin trough concen-
trations and AUCs has renewed our interest in calculating AUCs in prac-
tice. Despite the clear advantages associated with AUC vs. trough-only
monitoring for gauging the probability of efﬁcacy while minimizing
likelihood of AKI, there has been considerable reluctance by clinicians
to move away from trough-only monitoring. Although calculating the
AUC by the linear-trapezoidal formula is relatively straightforward [5],
it is often too cumbersome to collect multiple levels over one dosing in-
terval in the clinical arena. To address this issue, our group recently
identiﬁed two simpliﬁed approaches for estimating AUC values with
low bias and high precision using only one or two antimicrobial concen-
trations [14,15]. This article will review the contemporary understand-
ing of the pharmacokinetic/pharmacodynamic (PK/PD) proﬁle of
vancomycin and describe two innovative methods for computing the
AUC in clinical practice based on one or two samples. We will also
discuss the additional information required to improve the delivery of
vancomycin in future patients.
2. Pharmacodynamic proﬁle of the “15–20 mg/L” target serum
vancomycin concentration
Our current understanding of the vancomycin PK/PD proﬁle is best
summarized in the 2009 consensus review by the Infectious Diseases
Society of America, the Society of Infectious Diseases Pharmacists and
the American Society of Health-Systems Pharmacists [4]. Their statement
represents the ﬁrst set of national, evidence-based recommendations forvancomycin dosing andmonitoring.While a variety of PK/PD targets have
been suggested for vancomycin, they concluded that the AUC/MICBMD
ratio is the optimal predictor of efﬁcacy for vancomycin based on the
best available data [4]. The experts proposed that the data—drawn from
animal models, in vitro studies, and limited human studies—collectively
suggests that microbiologic success is optimized when the vancomycin
AUC/MICBMD ratio exceeds 400 [3,4,16–19].
Since it is difﬁcult in the clinical setting to obtain multiple serum
vancomycin concentrations to determine the AUC and subsequently
calculate the AUC/MICBMD ratio, the expert guidelines recommend
monitoring trough serum concentrations as a surrogate marker for
AUC [3,4]. Their conclusion reads as follows: “Based on the potential
to improve penetration, increase the probability of optimal target
serum vancomycin concentrations, and improve clinical outcomes for
complicated infections such as bacteremia, endocarditis, osteomyelitis,
meningitis, and hospital-acquired pneumonia caused by S. aureus,
total trough serum vancomycin concentrations of 15–20 mg/L are
recommended”[3,4].
Despite its subsequent widespread integration in clinical practice,
the clinical beneﬁts of maintaining higher vancomycin trough values
have not been well described. To date, seven published studies of note
have evaluated the relationship between vancomycin trough values
and clinical outcomes [6–11,20]. No link between clinical success and
vancomycin trough values was seen in six of the seven studies that ex-
amined this relationship [6–11]. The seventh study by Kullar et al.,
showed that vancomycin failure (a composite endpoint including dura-
tion of bacteremia, recurrence, and mortality) was higher in patients
(58–66%) with vancomycin trough concentrations less than 15 mg/L
compared to those obtaining trough concentrations between 15 and
20 mg/L (40%). However, at the upper end of the trough continuum,
treatment failure again increased in patients with vancomycin trough
concentrations N20 mg/L [20].
From a PK/PD perspective, it is not altogether surprising that there is
a paucity of clinical data to support the range of 15–20 mg/L for vanco-
mycin serum trough concentrations. The current Clinical Laboratory
Standards Institute (CLSI) and Food andDrug Administration (FDA) sus-
ceptibility breakpoint for vancomycin against S. aureus is ≤2 mg/L [21,
22]. However, maintaining vancomycin trough concentrations between
15 and 20 mg/L only ensures a high likelihood (N90%) of achieving an
AUC/MICBMD ratio N400 for S. aureus isolates with vancomycin MIC
values ≤ 1 mg/L [13,23]. Using vancomycin PK data from patients
varying degrees of renal function, we demonstrated that against
S. aureus isolates withMIC values of 2mg/L, the probability of obtaining
an AUC/MICBMD ratio N400 with trough vancomycin concentrations be-
tween 15 and 20 mg/was suboptimal and was a function of the total
daily dose administered (Fig. 1) [13]. In contrast, the probability of
achieving an AUC/MICBMD in excess of 400 was 100% for MIC values
≤1 mg/L (Fig. 1). Further study is needed, but these data suggest that
the current dosing approach ofmaintaining trough vancomycin concen-
trations between 15 and 20 mg/L will have a low probability of success
for infections due to MRSA with wild-type MIC values by broth
microdilution at the upper end of the antibiotic susceptibility range
(e.g., 1.5 to 2 mg/L).
3. Mathematical relationship between trough and AUC
As mentioned previously, the trough is a single exposure point esti-
mate at the end of the dosing interval. For vancomycin and most drugs,
the trough concentration just prior to the next dose is the lowest con-
centration observed in the dosing interval. As such, the 24-hour AUC
value (AUC24) associated with trough values of 15–20mg/L will almost
always lead to an AUC24 in excess of 400 mg∗L/h. As an example, main-
taining a vancomycin trough concentration of 17.5 mg/L equates to an
AUC24 N 420 mg∗L/h (17.5 mg/L × 24 h). Therefore, the probability of
achieving an AUC/MICBMD ratio ≥400 will always be 100% with vanco-
mycin trough values between 15 and 20 mg/L when the MIC value is
Fig. 1. Probability of achieving an AUC/MIC ratio≥400 for vancomycin dosing regimens of
varying intensity when trough vancomycin concentrations are between 15 and 20 mg/L.
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AUC values of at least 400 mg∗L/h, there is considerable variability in
the upper range of AUC values. This can be shown through a Monte
Carlo simulation (n = 5000) of the vancomycin concentration-time
proﬁle based on the administration of a 1 g every 8 hour regimen
using a well-established population PKmodel [13,24,25].When one ex-
amines the relationship between the trough concentration after the
third dose and AUC24 (Fig. 2), a trough concentration will not explain
more than approximately 50% of the inter-individual variability in the
AUC (R2= 0.409). Therefore, one cannot rely solely on the vancomycin
“15–20 mg/L” trough concentration range to achieve an AUC/MICBMD
ratio ≥400 for S. aureus isolates with MIC values in excess of 1 mg/L.
4. Concerns of acute kidney injury with trough vancomycin
concentrations of 15–20 mg/L
Due to the reluctance to estimate AUC values at the bedside, the lim-
ited data in support of the 15–20 mg/L range for vancomycin serum
trough concentrations has raised the question of whether we need to
maintain even higher trough values in clinical practice. There are two
things to consider when evaluating drug therapy. First, the drug must
be efﬁcacious. Second, the drug must be non-toxic. While maintenanceFig. 2. Scatter and linear ﬁt plot of vancomycin area under the curve over 24 h (AUC24)
versus trough vancomycin concentration from 5000 subject Monte Carlo simulation.of trough concentrations in excess of 20mg/Lwill ensure a higher prob-
ability of achieving anAUC/MICBMD ratio N400 for S. aureus isolates with
MIC values N1 mg/L, this may not be possible without subjecting
patients to an increased risk of vancomycin-related toxicities, most
notably AKI [6–9,11,19,20,26–55]. Nephrotoxicity is a long-standing,
yet highly debated, adverse effect associatedwith vancomycin adminis-
tration [56,57]. To date, 14 studies [6–9,11,20,22,26,27,30,32–34,36,47]
of note have comparatively assessed the AKI potential of maintaining
higher vancomycin trough concentrations (N15 mg/L) relative to
lower troughs (b15 mg/L) in clinical practice and the results of these
studies are well summarized in the systematic literature review by
Van Hal et al. [12]. Overall, maintaining trough concentrations in excess
of 15mg/L was found to substantially increase the risk of a nephrotoxic
event (OR 2.74; 95% CI 1.94–3.88, p b 0.01) relative to trough concentra-
tionsb15mg/L. The probability of a nephrotoxic eventwas also found to
increase as a function of treatment duration, with most episodes occur-
ring after seven days of therapy [12]. Collectively, these data strongly
suggest that adherence to the recommendations for vancomycin
serum trough concentrations in recent expert guidelines [3,4] may re-
sult in an elevated risk of vancomycin-induced AKI.
As noted above, there is a high degree of inter-individual variability
between a measured trough concentration and the actual AUC value
[13]. Therefore, it is difﬁcult to estimate the degree of AKI associated
with a given trough concentration due to the wide range of AUC values
associated with it. There have been limited attempts in the literature to
quantify the relationship between AUC and the probability of AKI [32,
58]. While data are scant, an AUC range of 700–1300 mg h/L has been
suggested to increase the risk of nephrotoxicity [14,32,58,59]. Suzuki
et al. [58], compared the mean vancomycin AUC in patients who were
nephrotoxic and non-nephrotoxic in a recent case–control study. Most
patients in the nephrotoxic group had AUC24 values between 600 and
800 mg∗h/Lwhile thosewho remained non-nephrotoxic were between
400 and 600 mg∗h/L (p= 0.014). Our group also recently examined the
relationship between AUC and occurrence of AKI among hospitalized
patients receiving vancomycin [32]. In contrast to Suzuki et al. [58],
we found that the probability of AKI increased 2.5-fold among patients
with AUCs above 1300 mg∗h/L compared with those below (30.8% vs.
13.1%, p = 0.02) [32]. Interestingly, although AUC values in excess of
1300 mg∗h/L were associated with a substantial increase in AKI, an
AUC exposure-response relationship appeared to exist (Fig. 3) [59]. In
particular, the probability of a nephrotoxic event increased as a function
of the AUC and patient's body weight [59]. Collectively, these limited
data suggest that vancomycin-induced AKI occurs along a continuum
and that certain populations may be at particular risk.Fig. 3. Probability of nephrotoxicity versus vancomycin area under the curve from time 0
to 24 h (AUC0–24) by body weight breakpoint.
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The efﬁcacy data, combined with the AKI ﬁndings, suggest that
trough-only monitoring is not sufﬁcient to guide vancomycin dosing
and that AUC-guided dosing may be warranted [13]. Until recently,
AUC determination has required one to collect multiple PK samples
and calculate the AUC by linear-trapezoidal formula. Cognizant of the
practical difﬁculties associated with this approach, our group has
recently identiﬁed two simpliﬁed methods for estimating AUC values
in practice with low bias and high precision using only one or two
serum antimicrobial concentrations [14,15]. One approach involves
the use of population modeling and Bayesian software programs to
optimize the delivery of vancomycin based on the collection of one
vancomycin trough concentration [14]. The other approach relies on
ﬁrst-order pharmacokinetic equations based on the collection of two
timed steady-state serum vancomycin concentrations to estimate the
AUC value [15]. Each will be discussed in turn.
5.1. Bayesian approach
The Bayesian dosing approach is based on Bayes' Theorem. In the
context of PK/PD, his theorem describes quantitatively the important
sequential relationship between: (1) the estimated probability distribu-
tion of an individual patient's PK parameter values (e.g. volume or
clearance) prior to administering the drug based on the way the drug
has behaved in prior patients (Bayesian prior); (2) the measured drug
concentrations that are collected from a patient after administration of
a given drug regimen, and (3) the revised probability distribution of a
givenpatient's PK parameter values after dosing and drug concentration
data is taken into account (Bayesian conditional posterior). With the
Bayesian conditional posterior, the vancomycin AUC value can be
estimated with low bias and subsequent AUC-optimized dosing recom-
mendations can be provided in real-time [60–63].
A common analogy that is used to explain a Bayesian approach is as
follows. A person misplaces their mobile phone in their home. A stan-
dard approach may be to call the phone number from another line
and hope that the ringtone is loud enough to locate the missing
phone. A Bayesian approach recognizes through prior experience (a
priori probability) that the person often misplaces their phone in the
bedroom. Given this information, the person asks the family member
to place the call when they are closer to the bedroom to maximize the
probability of ﬁnding the phone (a posteriori probability). If the phone
is not found in the bedroom, the person moves to the next probable
location and repeats the step (second iteration). A similar iterative ap-
proach can be used to identify an individual PK proﬁlewith limited data.
Using richly sampled serum vancomycin concentration-time data
from three studies comprising 47 adults with varying renal function,
our group determined that trough-only data can be used to generate ac-
curate and reliable estimates of the daily AUC through the use of a
Bayesian software program embedded with a PKmodel based on richly
sampled vancomycin data as the Bayesian prior (Bayesian estimation
technique) [14]. Assuming that the AUC estimated from the full data is
the “gold standard”, the Bayesian approach with trough-only data
was associated with 97% (93% - 102%, p = 0.23) accurate AUC estima-
tion [14]. In contrast, the traditional trough-only PK approach
underestimated the true AUC by about 25%. Of note, the Bayesian
approach with trough-only data requires the use of a PK model based
on richly sampled PK data as the Bayesian prior. Use of a population
PKmodel that was derived on peak and trough serum vancomycin con-
centrations as the Bayesian prior was suboptimal at predicting the true
AUC from vancomycin troughs. We make this distinction since many
published vancomycin population models are derived from peak and
trough concentration data only [14].
Bayesian dose optimizing software is now readily available and they
can be used at the bedside to identify the optimal vancomycin dosagethat achieves the pre-deﬁned AUC target [64]. Bayesian programs offer
numerous advantages over the traditional ﬁrst-order equation ap-
proach. Vancomycin concentrations can be obtained at any time, even
over different dosing intervals. The generality of the Bayesian method
allows for application of various pharmacokinetic models (in this
case a 2-compartment model for vancomycin) and dosing patterns.
Additionally, this approach is not limited to trough-only sampling and
samples do not necessarily have to be taken under steady-state condi-
tions [61,62].
To estimate the AUC based on dosing history and provide subse-
quent AUC-dose optimized recommendations, the Bayesian software
only requires four speciﬁc components: (1) the structuralmathematical
model that best describes the pharmacokinetics of a given agent; (2) a
density ﬁle, which contains the parameter estimates and their associat-
ed dispersion for the embedded structural PK model (Bayesian prior);
(3) a patient ﬁle that contains their drug dosing and collected PK data;
and (4) a patient “target” ﬁle which contains the target exposure proﬁle
and initial estimates of future dosing regimens. In short, the dose opti-
mization software uses the equations in the structural mathematical
model ﬁle and the population Bayesian prior in the density ﬁle, together
with the individual patient's observed drug concentrations in the data
ﬁle to calculate a Bayesian posterior parameter value distribution for
that patient. The dose optimization software then calculates the optimal
dosing regimen based on the speciﬁed exposure proﬁle in the target ﬁle
[61,62,64]. In simpler terms, it is a step-wise mathematical approach
that increases the probability of ﬁnding “the missing cellphone” based
on available information (see analogy above).
The additional advantage of this approach is that it can be modiﬁed
to be an adaptive program [61]. Innovative treatment schemas such as
front-loading doses with a transition to a lower maintenance dosing
regimen can be designed to rapidly achieve target concentrations with-
in the ﬁrst 24 to 48 h among critically ill patients. Furthermore,
concentration-time information does not need to be collected at
“steady-state” (after the 3rd or 4th dose). Dynamic changes in PK pro-
ﬁles readily occur in patients, especially those in the critical care settings
that limit the ability of “steady-state” concentration monitoring. With
the Bayesian approach, vancomycin concentrations can be collected
within the ﬁrst 24 to 48 h, rather than waiting for steady-state condi-
tions, and this information can be used to inform subsequent dosing
(adaptive feedback control). Furthermore, the Bayesian approach pro-
vides the ability to include covariates, such as creatinine clearance, in
the structural PK models (Bayesian prior density ﬁle) that account for
the pathophysiological changes that readily occur in critically ill pa-
tients. Incorporation of covariates that account for these “dynamic”
changes serve as a way to identify dosing schemes that optimize effect
and predict future dosing in a patient with an evolving PK proﬁle [61].
This requires further study, but it is an approach commonly used in
other ﬁelds, such as the military for targeting an incoming missile im-
pacted by dynamic conditions such as wind speed and direction. Alter-
natively, as stated above, amore pragmatic approachwould be frequent
observation and dosage adjustment (adaptive feedback control)
performed with minimal delay between observation and adjustment.
5.2. Equation-based approach
As an alternative to using a Bayesian software program, we recently
demonstrated that use of post-distributional peak (1–2 h post infusion)
and trough concentrations can determine the daily AUC value with rea-
sonable precision and low bias with simple ﬁrst-order PK formulas [15,
65]. The collection of two PK samples during the same dosing interval,
such as a peak and a trough concentration, permits characterization of
the concentration-time proﬁle for that dosing interval as a simple
mono-exponential curve. Simple arithmetic equations can be applied
to calculate the AUC using this approach. Importantly, this approach
could be programmed into the electronic medical system to automati-
cally compute the AUC. The major advantage of this approach is that it
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patient-level information for rapid clinical translatability. The major
limitation of this approach is that it is not adaptive like the Bayesian
approach, and can only provide a snapshot of the AUC for the sampling
period. This AUC calculation will not be correct if a physiologic change
such as renal dysfunction occurs during or after the sampling period.
The equations to compute AUC from two samples are based in part
on an original approach proposed by Begg, Barclay, and Duffull for ami-
noglycosides [66] and modiﬁed by Pai and Rodvold [15]. This approach
has recently been validated for computation of daptomycin AUC [65].
However, these previous investigations are based on the assumption
that these agents are administered using a once-daily approach. This is
often not the case for vancomycin because twice daily and thrice daily
dosing in patients with good kidney function is common. The AUC
computation may be modiﬁed based on two concentrations as follows.
Fig. 4 reﬂects the concentration-timeproﬁle of vancomycin based on
the administration of 1000 mg every 8 h (1-hour infusion) and focuses
on theproﬁlewhere TDM is often employed (around the3rd or 4th dose
[at 24 h to 32 h time points of therapy]). As illustrated, the “true” vanco-
mycin concentration follows at least a bi-exponential decline (2-
compartment model). It is not possible to accurately characterize the
initial (α-phase) concentration-time proﬁle without measurement of
a concentration between the end of infusion and the moment in the
curve that occurs 2–3 h from the start of infusion. Because two concen-
trations may be measured during the same phase (β-phase) of the
concentration–time decline, it is possible to ﬁt a mono-exponential
decline function to characterize this proﬁle from the start of infusion
(artiﬁcial time) to the end of the dosing interval. This ﬁt is also illustrated
in Fig. 4.
The Sawchuk–Zaske method [67] can be used for this mono-
exponential ﬁt by computing the elimination rate constant (Ke) using
the following equation.
Ke ¼
Ln
C1
C2
 
t
ð1Þ
where, C1 is theﬁrst concentration after the dose thatmay be referred to
as the “peak” concentration, C2 is the second concentration collected
toward the end of the dosing interval or “trough” concentration, and t
is the difference in time between these two concentrations. Once the
Ke is computed, this information can be used to compute theoretical
concentrations through back-extrapolation (end of infusion or start ofFig. 4. Expected concentration-time proﬁle after administration of the 4th dose of a 1000
mg every 8 hour regimen of vancomycin with a peak and trough concentration ﬁt with a
mono-exponential decline function.infusion value). This method can also be used to forward-extrapolate
concentrations to the “true” trough concentration (Ct) at the end of
the dosing interval. This may be necessary because it is often not clini-
cally possible to measure the trough concentration exactly at the end
of the dosing interval.
Once the theoretical (i.e., notmeasured) concentrations at the end of
infusion (Ceoi), start of infusion (Csoi), and Ct are known, AUC can be
calculated using arithmetic functions. In the ﬁrst scenario (Fig. 5), the
end of infusion concentration is estimated. The start of infusion and
trough concentration can be assumed to be the same because they are
at near-steady state (Fig. 4), which permits superposition. Alternatively,
samples may be collected prior to the dose (trough) and after the dose
(peak) to expedite AUC calculation (instead of waiting until the end of
the dosing interval).
The area between the start (same as Ct) and theoretical end of
infusion (Ceoi′) for a given infusion time (t′) can be related as the area
of a trapezoid:
AUCt0−t1 ¼ Ceoi 0 þ Ct
  0:5 t0 ð2Þ
The area under a mono-exponential curve from the time of the end
of infusion (t1) to the time of the end of the dosing interval (t2) is:
AUCt1−t2 ¼
Z infinity
t1
Ceoi0  e−Ke tð Þdt−
Z infinity
t2
Ct  e−Ke tð Þdt
AUCt1−t2 ¼
Ceoi0− Ct
Ke
:
ð3Þ
So the area under scenario 1 can be simpliﬁed to
AUCt0−t2 ¼
t0  Ceoi 0 þ Ct 
2
þ Ceoi
0−Ct
Ke
: ð4Þ
As shown by Fig. 5, this approach captures a majority of the area but
will under-predict the true AUC as the rise in concentration to the end of
infusion is not entirely linear and theα-phase is ignored by thismethod.
An alternative to overcome this limitationwould be to back-extrapolate
the concentration to the theoretical start of infusion (Csoi′). Under this
second scenario (Fig. 6), the equation can be simpliﬁed to:
AUCt0−t2 ¼
Z infinity
t0
Csoi0  e−Ke tð Þdt−
Z infinity
t2
Ct  e−Ke tð Þdt
AUCt0−t2 ¼
Csoi 0− Ct
Ke
ð5ÞFig. 5. Expected area under the curve captured using Eq. (4) based on an expected vanco-
mycin concentration time proﬁle.
Fig. 6. Expected area under the curve captured using Eq. (5) based on an expected vanco-
mycin concentration time proﬁle.
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and will substitute for the AUC not captured by Eq. (4). However, as il-
lustrated, this approach will slightly over-predict the true vancomycin
AUC. Under all these scenarios, the AUC24 will be a function of the num-
ber of identical doses administered during that interval. Thus, in the
speciﬁc example presented, the computation will lead to AUC estima-
tion over an 8 hour interval (AUC8). The AUC24 can be calculated by
multiplying this estimate by 3 (AUC8 × 3).
5.3. Comparison of the equation-based to Bayesian based approach to AUC
calculation
We have previously described the dataset used to validate the
single-measurement based Bayesian AUC calculation using data from
themanuscript fromour recent group [14]. Concentrations collected be-
tween 1.5 and 3 h from the start of infusionwere used as the Cp and the
concentration close to the end of the dosing interval was selected as Ct.
Vancomycin AUC was calculated separately using Eqs. (4) and (5). The
equation-calculated AUC was compared to the Bayesian AUC using the
full concentration-time proﬁle (AUCf) and a value based on a trough-
only measurement (AUCt). Table 1 summarizes the median [5th and
95th] percentile AUC values and the ratio of the trough only or peak
and trough based AUC calculation to the reference standard (AUCf). As
shown in Table 1, the proposed methods accurately (low bias and
high precision) reﬂect the reference AUCf value. As expected from de-
scriptions of Eqs. (4) and (5), (4) tends to under-predict AUCf while
Eq. (5) tends to over-predict AUCf. However the median error is ≤2%
by these methods, which is not clinically signiﬁcant.
A key issue to consider when applying the equation-based approach
is the optimal sampling window for collection of the peak concentra-
tion. A sample collected too early for example may be in the α-phase
and lead to an erroneous Ke estimate. Given that it is not practical to col-
lect multiple samples after the end of infusion to identify the optimalTable 1
Median [5th, 95th percentile] area under the curve (AUC) values, ratio of computed to referen
methods for AUC estimation.
AUC estimation method Number of samples AUC (mg∗h/L
Bayesian All 250 [84.1, 688
Bayesian Trough only 259 [82.9, 573
Eq. (4) Peak and trough 239 [90.6, 662
Eq. (5) Peak and trough 247 [100, 675peak sampling time-point, we used a population simulation to address
this question. We simulated 5000 concentration-time proﬁles based
on the administration of three 1500 mg (1.5 h infusion) vancomycin
doses. We tested 45 Cp–Ct pairs that included 9 Cp values between 1 h
and 3 h from the endof infusion (15 minute increments) and 5 Ct values
in 15 minute incrementswithin anhour before the end of the dosing in-
terval. This simulation revealed that the mean percent error in the AUC
calculation using Eqs. (4) or (5) is b2% when the Cp value is collected
1.75 h to 3 h after the end of infusion.
6. Future directions
Several things should be noted when interpreting and applying the
ﬁndings from this review. Contemporary vancomycin dosing focuses
on achieving an AUC/MICBMD ratio ≥400. Although the AUC/MICBMD
≥400 PK/PD target for vancomycin is the prevailing PK/PD target [3,4,
16–19], data in support of this target is largely derived fromneutropenic
mouse thigh infectionmodel data [16] and there are limited clinical data
to support this target [3,4,18,47,68]. Furthermore, most clinical evalua-
tions performed to date that identiﬁed AUC/MICBMD≥400 as the critical
PK/PD target for vancomycin used a simple formula based on daily
vancomycin dose and estimated renal function to estimate AUC values
[18,47,68]. In most cases, they used the Cockcroft–Gault creatinine
clearance formula [69]. As highlighted throughout this manuscript,
there is considerable inter-patient variability in vancomycin exposure
proﬁles in clinical practice and it is difﬁcult to generate valid estimates
of exposure variables in a given individual based on glomerular
ﬁltration estimation formulas alone [9–11].
Using the validated Bayesianmethod discussed in thismanuscript to
estimate the vancomycin exposure proﬁle with limited vancomycin
blood concentration data [14], our group determined that AUC/MICBMD
is the pharmacodynamic indexmost closely linked to outcomes for van-
comycin among adult patients with MRSA bloodstream infections [70].
In contrast to the reported AUC/MICBMD ratio of 400 [18,47,68], the crit-
ical day 1 and day 2 AUC/MICBMD ratio values identiﬁed by classiﬁcation
and regression tree (CART) analysis were AUC0–24h/MICBMD ≥521 and
AUC0–24h/MICBMD ≥650. Achievement of both day 1 and day 2 AUC/
MICBMD values in excess of the CART-derived AUC/MICBMD breakpoints
were associated with success rates of 80–85%, consistent with the near
maximal effect expected for patients with MRSA BSIs; failure to achieve
the CART-derived AUC/MIC exposure thresholds was associated with
success rates below60%. Collectively, these ﬁndings establish the critical
importance of individualized estimates of the daily AUC/MICBMD ratio
during the ﬁrst two days of vancomycin therapy [70]. As this was a ret-
rospective study, these data also provide justiﬁcation to support a larger-
scale, multi-centered clinical trial to prospectively validate the ﬁndings
and determine the vancomycin pharmacokinetic/pharmacodynamic
(PK/PD) proﬁle associated with maximal effect. For any drug, a clear un-
derstanding of the PK/PD target associatedwithmaximal effect is needed
to optimally dose it in clinical practice.
Similar to the “efﬁcacy” exposure-response data, our understanding
of the relationship between vancomycin exposure and probability of
AKI is limited. Most studies performed to date have examined the
relationship between vancomycin trough concentration and AKI at
pre-deﬁned thresholds [12]. The more quantitative analyses indicatece AUC values, and coefﬁcient of determination (R2) for the Bayesian and equation based
) Ratio of computed AUC to reference AUC R2
] Reference Reference
] 1.0 [0.74, 1.28] 0.948
] 0.99 [0.83, 1.16] 0.971
] 1.02 [0.85, 1.22] 0.987
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hood varies by patient population [32,58,59]. However, the ﬁndings
have varied. To truly optimize the dosing of vancomycin, a ﬁrmer
understanding of the PK/PD targets associated with maximal effect
and minimal AKI are required. No model can be proven but rather
only disproven. So, additional work is always needed to ensure general-
izability of any AUC/MIC target to broader patient populations.
Given that vancomycin TDM occurs routinely in clinical practice,
clinicians involved in improving optimal dose delivery must have tools
to accomplish this goal. The state-of-the-art approach that will be adap-
tive to dynamic patient conditions is the Bayesian approach [14,60–62].
Several software programs and trainingmodules exist to empower clini-
cians to adopt this approach for vancomycin in clinical practice [64]. An
important future direction is for clinicians who perform vancomycin
TDM to learn this tool for dose optimization if they wish to only rely
on a single point measurement (vancomycin serum trough concentra-
tion). We have clearly laid out the fallacies of a single-point measure-
ment when it is not coupled with this software tool.
An alternative (but less ideal solution) would be to apply an
approach that is currently applied with aminoglycoside dosing that in-
cludes peak and trough concentrations [15,65,71]. Instead of treating
these two values as independent terms, they can be integrated by an
analytic solution to derive a reasonable estimate of vancomycin AUC.
This estimate of AUC will be a static representation of information for
the speciﬁc sampling period but is a step above trough-only or peak-
only concentration interpretation. The increasing use of electronic med-
ical systems including technologies that scan the exact (or close to)
times that doses are administered and samples collected provides an op-
portunity for automation of this calculation. An important future direc-
tion could be automation of vancomycin AUC output value if peak and
trough concentrations are measured in clinical practice using Eqs. (1),
(4) or (5).
7. Conclusions
We live in an age where personalized medicine and individualized
therapies are recognized modalities to improve the safety and efﬁcacy
of medications. A one-size-ﬁts-all approach to drug dose delivery is no
longer reasonable. Dose delivery optimization requires measurement,
and in the case of vancomycin that currently includes measurement of
a trough concentration. Interpretation of a trough concentration as an
independent value ignores the true concentration–time proﬁle in a
given patient. A Bayesian approach can overcome this major limitation
by using prior probabilistic information to ﬁt the trough-only measure-
ment to a more realistic proﬁle. This approach requires a Bayesian prior
generated from the rich data repository that exists for vancomycin.
Alternatively, a lesser solution that could more easily be automated
for clinical use includes the application of an analytic solution but it re-
quires peak and trough concentration measurement. While there will
always be barriers to implementation of these approaches, these are
“largely logistic and educational, but not technological” [14]. Clinicians
who routinely use vancomycin TDM must ultimately decide upon the
best solution for their clinical practice. We believe that the best solution
is the Bayesian approach, but offer an alternative for centers that do not
yet have the expertise to implement this approach.
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